Ram Venkatesh ANANTHA,John K. MCCORMICK,S.M. Mansour HAERYFAR
申请号：
US15303466
公开号：
US20170027973A1
申请日:
2015.04.10
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present disclosure is directed to the modulation of in variant Natural Killer T Cells (iNKT Cells) using a Th2-polarizing iNKT Cell agonist, such as an α-galactosylceramide, synthetic glycolipid OCH, or C20:2 α-galactosylceramide analog. Said Th2-polarizing iNKT Cell agonists are used the treatment of sepsis and/or apoptosis in a subject. A method of diagnosing early stage sepsis in a subject by measuring a ratio of circulating iNKT cells relative to total circulating T cells in a subject is also disclosed.
